Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines in the United Kingdom. Its lead drug candidate consists of OCT461201, a cannabinoid like new chemical entity, which is in phase I clinical trial for potential therapy to peripheral neuropathies and irritable bowel syndrome. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia; OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indication; and immunotherapy agents for the treatment of solid tumours. In addition, the company is involved in pharmaceutical research. The company was founded in 2017 and is based in London, the United Kingdom.